Galderma's Nemolizumab Shows Sustained Efficacy in Young Atopic Dermatitis Patients
Event summary
- Galderma's nemolizumab demonstrated sustained symptom relief in children aged 2–11 with moderate-to-severe atopic dermatitis through Week 52 of a Phase II trial.
- The study showed 56%–72% response rates in itch reduction and 70%–78% improvement in sleep disturbance by Week 16, with further gains at Week 52.
- Nemolizumab was well tolerated with no new safety signals, aligning with its established profile in adults and adolescents.
- The data will be presented at the PeDRA Annual Conference on October 15–17, 2026.
The big picture
Galderma's Phase II data for nemolizumab in young children addresses a critical unmet need in pediatric dermatology, where treatment options for moderate-to-severe atopic dermatitis are limited. The sustained efficacy and safety profile could position nemolizumab as a key player in this underserved market, potentially expanding its global reach beyond current adolescent and adult indications. The results also highlight Galderma's commitment to dermatology innovation, reinforcing its leadership in the category.
What we're watching
- Regulatory Expansion
- Whether Galderma can secure approvals for nemolizumab in younger pediatric populations, given current indications start at age 12.
- Market Positioning
- How these results may strengthen nemolizumab's competitive edge against existing therapies for pediatric atopic dermatitis.
- Commercial Strategy
- The pace at which Galderma can translate Phase II data into Phase III trials and potential label expansions.